PCLAF and melanoma: Notably, studies by Im and colleagues provided the first report demonstrating that a single systemic administration of PAF can augment IL-1α and TNF-α-induced increased pulmonary metastasis of murine B16F10 melanoma cells in syngeneic C57BL/6 hosts, in a process blocked by the PAFR antagonist BN50739 (31).